Danish pharmaceutical giant Novo Nordisk, the maker of Ozempic and Wegovy, has announced it will shorten its public-facing brand to simply “Novo” as part of a broader corporate culture overhaul, alongside a new slogan, “Lasting Health Starts Now.” The company’s legal name remains Novo Nordisk A/S, and the Apis bull logo has been retained, but the simplified name is intended to sharpen the company’s identity in an increasingly competitive obesity drug market.
Why the rebrand
CEO Mike Doustdar framed the change as “strategically important” for lifting performance and market visibility, saying the company wants to “move with focus and speed” in a market that has become more consumer-driven. The new corporate culture push, dubbed “The Novo Way,” centres on four principles: customer obsession, competitiveness, clarity, and care and integrity.
A widening gap with Eli Lilly
The rebrand comes as Novo has continued to lose ground to rival Eli Lilly in the global obesity drug race. As of the second quarter of 2026, Eli Lilly held roughly 60–61% of the obesity drug market compared with Novo’s 38–39%, according to reporting on the announcement. Novo shares have fallen sharply over the past year — down close to 20% over twelve months and roughly 15% year-to-date — following a steep decline from the company’s 2024 peak, when it was briefly Europe’s most valuable listed company.
One bright spot cited by the company is its oral formulation of Wegovy, which reached around 3 million prescriptions by the end of June 2026. Novo says it will lay out more detail on its refreshed strategy at a Capital Markets Day in London on 21 September 2026.
Why it matters for South Africa
Novo Nordisk is an active player in the South African weight-loss and diabetes market, having launched Wegovy locally and pursued a lower-cost Ozempic alternative through a local partnership, as well as pressing its court case against compounding pharmacy iDexis over unregistered semaglutide products. A sharper, more consumer-focused global strategy from Novo — and continued competitive pressure from Eli Lilly’s Mounjaro, distributed in Africa by Aspen Pharmacare — is likely to keep shaping pricing, marketing and supply decisions in the South African market over the coming months.
What this means for patients
- No immediate change to product names, pricing or availability of Ozempic or Wegovy in South Africa is expected from the rebrand itself; the change is corporate branding and strategy, not a product change.
- Intensifying global competition between Novo and Eli Lilly could, over time, influence pricing and the pace at which newer formulations (such as oral GLP-1 options) reach the South African market.
- Patients should watch for further detail from Novo’s Capital Markets Day on 21 September 2026, which may signal future pipeline or market priorities relevant to Wegovy and Ozempic availability in SA.
- As always, patients should rely on official SAHPRA-registered product information rather than global corporate news when making treatment decisions.
This article is for general information purposes only and does not constitute medical or financial advice. Always consult a registered healthcare professional before starting, stopping, or switching any medication, and consult a qualified financial adviser before making investment decisions.
Sources
- Novo Nordisk changes name to ‘Novo,’ updates strategy — UPI, 14 September 2026
- Novo Nordisk rebrands as ‘Novo,’ part of a culture shift — STAT News, 14 September 2026
- Novo Nordisk rebrands as Novo to compete in obesity market — Yahoo Finance, 14 September 2026
- Novo Nordisk Shortens Name to Novo in Obesity Drug Market Push — Bloomberg, 14 September 2026